Petros Pharmaceuticals, Inc.
Income Statement
| Line Item | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $725.4K | $1.6M | $1.4M | $1.4M | $-364.3K | $1.7M | $2.0M | $2.5M |
| Cost of Revenue | $264.8K | $287.0K | $329.1K | $331.8K | $158.1K | $408.5K | $513.9K | $550.7K |
| Gross Profit | $460.6K | $1.3M | $1.1M | $1.1M | $-522.4K | $1.3M | $1.5M | $2.0M |
| Gross Margin | 63.5% | 81.8% | 76.8% | 76.1% | 143.4% | 75.6% | 74.2% | 78.1% |
| Operating Expenses | ||||||||
| Research & Development | $101.9K | $588.4K | $368.8K | $1.6M | $834.3K | $389.1K | $866.6K | $319.1K |
| SG&A Expense | $577.6K | $1.2M | $1.3M | $1.5M | $2.9M | $2.0M | $2.2M | $2.1M |
| Operating Income | $-577.6K | $-1.2M | $-1.3M | $-1.5M | $-5.0M | $-4.8M | $-2.5M | $-1.3M |
| Operating Margin | -79.6% | -76.0% | -94.9% | -108.2% | 1,383.3% | -287.0% | -123.5% | -52.0% |
| Interest Expense | — | — | — | — | $125.8K | $131.4K | $136.8K | $142.2K |
| Pretax Income | $-552.8K | $-919.5K | $384.3K | $382.9K | $318.2K | $-4.5M | $-2.5M | $-1.4M |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-9.3M | $-2.2M | $-662.0K | $-2.2M | $318.2K | $-4.5M | $-2.5M | $-1.4M |
| Net Margin | -1,278.4% | -140.9% | -46.6% | -155.7% | -87.3% | -271.7% | -127.7% | -55.0% |
| EPS (Basic) | $-0.18 | $-0.19 | $-0.11 | $-0.48 | $-0.02 | $-0.03 | $-0.01 | $-0.01 |
| EPS (Diluted) | $-0.18 | $-0.19 | $-0.11 | $-0.48 | $-0.02 | $-0.03 | $-0.01 | $-0.01 |
| Shares Outstanding (Basic) | 27.9M | 34.2M | 25.7M | 16.6M | 189.3M | 184.4M | 184.2M | 181.7M |
| Shares Outstanding (Diluted) | 27.9M | 34.2M | 25.7M | 16.6M | 189.3M | 184.4M | 184.2M | 181.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |